Background. Complement C5 mediates pro-inflammatory responses in many immune-related renal diseases. Given that the C5a level is elevated in diabetes, we investigated whether activation of C5a/C5aR signalling plays a pathogenic role in diabetic nephropathy (DN) and the therapeutic potential of C5a inhibition for renal fibrosis. Methods. Human renal biopsies from patients with DN and control subjects were used for immunohistochemical staining of complement C5 components. Renal function and tubulointerstitial injury were compared between db/m mice, vehicle-treated mice and C5a inhibitor-treated db/db mice. A cell culture model of tubule epithelial cells (HK-2) was used to demonstrate the effect of C5a on the renal fibrotic pathway. Results. Increased levels of C5a, but not of its receptor C5aR, were detected in renal tubules from patients with DN. The intensity of C5a staining was positively correlated with the progression of the disease. In db/db mice, administration of a novel C5a inhibitor, NOX-D21, reduced the serum triglyceride level and attenuated the upregulation of diacylglycerolacyltransferase-1 and sterol-regulatory element binding protein-1 expression and lipid accumulation in diabetic kidney. NOX-D21-treated diabetic mice also had reduced serum blood urea nitrogen and creatinine levels with less glomerular and tubulointerstitial damage. Renal transforming growth factor beta 1 (TGF-b1), fibronectin and collagen type I expressions were reduced by NOX-D21. In HK-2 cells, C5a stimulated TGF-b production through the activation of the PI3K/Akt signalling pathway. Conclusions. Blockade of C5a signalling by NOX-D21 moderates altered lipid metabolism in diabetes and improved tubulointerstitial fibrosis by reduction of lipid accumulation and TGF-b-driven fibrosis in diabetic kidney.
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I N T R O D U C T I O N
Diabetic nephropathy (DN) is one of the common microvascular complications in diabetes and accounts for 30-40% of all cases of end-stage renal disease (ESRD) [1] . Renal fibrosis is the hallmark of progressive DN, with excessive deposition of extracellular matrix proteins in diabetic kidney accompanied by tubular atrophy and loss of renal vasculature. The extent of renal fibrosis is not only a marker of injury, but also a key determinant of the progression to ESRD [2] . Thus anti-fibrotic treatment has become an attractive therapeutic strategy for DN and there is an urgent need for understanding the mechanisms underlying renal fibrosis and developing a promising target to halt the disease [3, 4] .
Complement activation plays an essential role in renal inflammation and progressive renal diseases [5] . Although circulating complement proteins are mainly synthesized by the liver, local complement production was found in intrinsic renal cells, including tubular epithelial cells, glomerular mesangial and endothelial cells, leading to cytokine production and contributes to tubulointerstitial injury [6, 7] . Complement activation is implicated in most immune-mediated renal diseases. Complement C1q and C4 are strongly associated with lupus nephritis [8] . Treatment with anti-C5 antibody or complement inhibitor rCrry-Ig ameliorates the development of experimental lupus nephritis [9, 10] . Deposition of C3 is usually detected in renal biopsies from patients with immunoglobulin A (IgA) nephropathy. Increased tubular C5b-9 expression was correlated with tubulointerstitial expression of transforming growth factor beta 1 (TGF-b1) and renal fibrosis in idiopathic rapidly progressive glomerulonephritis [11] . Among the complement systems, complement C5a is the most effective mediator in inflammation by inducing secretion of interleukin 6 (IL-6), IL-8, tumour necrosis factor alpha (TNF-a) and CCL-2 [12] . C5a signalling is activated by interacting with two different receptors, C5aR and C5L2. C5aR is expressed on cell membrane that mediates most of the functional effects of C5a, whereas C5L2 is predominantly intracellular and may be a negative modulator of C5aR-mediated signal transduction [13] . In the kidney, C5aR is strongly expressed in tubular epithelial cells [14] while increased renal expression is found in glomerulonephritis that positively correlates to the degree of tubular atrophy and increases in serum creatinine levels, suggesting a role of C5a signalling in tubular injury [15] . Evidence has demonstrated that C5a mediates renal injury in ischaemia-reperfusion renal injury [16] , acute kidney allograft rejection [17] , lupus nephritis [18] and IgA nephropathy [19] . Interestingly, C5-deficient mice had reduced expression of fibrotic markers in the unilateral ureteral obstruction (UUO) model, suggesting a profibrotic role of C5 in the progression of CKD [20] . In this study we examined the levels of C5a and C5aR in renal biopsies from DN patients and investigated the contribution of C5a in the pathogenesis of DN in db/db mice with the use of a novel C5a inhibitor, NOX-D21, which is a mixed RNA/DNA aptamer that binds and inhibits mouse and human C5a. We also explored the mechanism underlying C5a-mediated renal fibrosis using a tubular cell culture model.
M A T E R I A L S A N D M E T H O D S
Human renal biopsies
The use of renal biopsies for this study was approved by the Research Ethics Committee or Institutional Review Board of the University of Hong Kong or Hospital Authority Hong Kong West Cluster. Renal tissues were obtained from patients with biopsy-proven DN (mean age of patients 58 years; mean haemoglobin A1c 6.6%; mean serum creatinine 364 mmol/L; mean proteinuria 5.80 g/24 h). The severity of DN (the degree of glomerulosclerosis, tubular atrophy and interstitial fibrosis) was obtained from a standard pathology report. Normal portions of renal tissues removed from nephrectomy specimens for the treatment of solitary renal carcinoma (mean age of patients 57 years; mean serum creatinine 88 mmol/L) in the opposite pole were used as controls.
Animal model
All work with mice was approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong and was performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male diabetic db/db (C57BLKS/JLepR db/db ) mice and their non-diabetic db/m (C57BLKS/JLepR db/þ ) littermates were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and underwent uninephrectomy (Unx) to hasten the development of DN, as described previously [21] . Unx mice were randomly divided into three groups: db/m, db/ db (vehicle) and db/db (NOX-D21). Mice were injected intraperitoneally with 10 mg/kg NOX-D21 (Noxxon Pharma, Berlin, Germany) every other day or with an equal volume of phosphate-buffered saline in the vehicle group. All mice were sacrificed after 12 weeks of treatment.
Cell culture
Human immortalized proximal tubule epithelial HK-2 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle medium/nutrient mixture F-12, supplemented with penicillin (100 IU/mL), streptomycin (100 mg/mL) and 10% foetal bovine serum (Invitrogen, Carsbad, CA, USA) at 37 C in 5% carbon dioxide atmosphere. Growtharrested HK-2 cells were stimulated with 50 ng recombinant C5a (R&D Systems, Minneapolis, MN, USA) for 0-120 min for pAkt level or pre-treated with LY294002 (10-20 mM) for 1 h and stimulated with C5a for 24 h for TGF-b secretion.
Histological analysis
Paraffin-embedded kidney tissue sections (4 mm) were stained with periodic acid-Schiff (PAS) solution (SigmaAldrich, St Louis, MO, USA) to assess glomerular mesangial expansion, sclerosis and tubular injury as described previously [22] . Twenty glomeruli per renal section were analysed under Â400 magnification. Glomerular mesangial expansion was graded with a semiquantitative index from 0 to 5 as follows: 0, normal; 1, slight glomerular damage and/or hyalinosis with focal adhesion involving <10% of the glomerulus; 2, sclerosis of 10-20%; 3, sclerosis of 20-30%; 4, sclerosis of 30-40%; 5, sclerosis >40%. Tubular injury was scored from 0 to 5 according to the percentage of damaged tubules (interstitial inflammation and fibrosis, tubular dilation, cast formation): 0, normal; 1, tubular lesion <10%; 2, 10-20% lesion; 3, 20-30% lesion; 4, 30-40% lesion; 5, >40% lesion. Histological analysis was performed in a blinded manner.
Immunohistochemical staining
Paraffin-embedded renal sections were deparaffinized, rehydrated and subjected to microwave-based antigen retrieval in citrate buffer. Sections were blocked with 2% bovine serum albumin buffer and stained with antibodies against C5aR (Hycult Biotech, Uden, The Netherland), C5a, Col I (Santa Cruz Biotechnology, Santa Cruz, CA, USA), fibronectin (Fn) (Sigma) and F4/80 (Serotec, Oxford, UK). The stained sections were incubated with peroxidase-conjugated secondary antibodies (Dako, Carpinteria, CA, USA) and were developed using DAB substrate from the EnvisionPlus system (Dako). The slides were counterstained with haematoxylin before mounting. Quantitative analysis of the staining was measured by Image-Pro Plus 6.0 and presented as a value of integrated optical density (IOD).
Blood and urine examination
Serum glucose level was measured by a Glucose Test Kit (Stanbio Laboratory, Boerne, TX, USA). Twenty-four-hour urine was collected by metabolic cage and urine albumin concentration was measured by a mouse albumin enzyme-linked immunosorbent assay (ELISA) kit (Bethyl Laboratories, Montgomery, TX, USA). Serum and urinary creatinine levels were measured by an enzymatic method (Stanbio Laboratory) and serum blood urea nitrogen (BUN), cholesterol and triglyceride levels were determined using commercial kits (Stanbio Laboratory). The serum C5a level was determined by an ELISA kit (Abcam, Cambridge, UK).
RNA extraction and real-time quantitative polymerase chain reaction (qPCR) analysis
Total RNA was extracted from renal tissue or cultured cells and reverse transcribed into cDNA. Real-time qPCR was performed using SYBR Green reagent on the StepOne Plus RealTime PCR System (Applied Biosystems, Carlsbad, CA, USA). Primers used for mRNA detection are listed in Table 1 . Relative gene expression was obtained after normalization with b-actin and followed by comparison with the control groups using SDS software (Applied Biosystems).
Western blot analysis
Total proteins were prepared from the kidney using RIPA lysis buffer (Millipore, Bedford, MA, USA). An equal amount of proteins was resolved in 4-12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel (Invitrogen) and transferred to a polyvinylidene fluoride membrane (Millipore). After blocking with 5% non-fat milk, the membranes were incubated with antibodies against TGF-b1 (Abcam), ColI (Santa Cruz Biotechnology), Fn (Sigma), phosphor-AKT, Akt (Cell Signaling Technology, Beverly, MA, USA) and adipose differentiation-related protein (ADRP; Novus Biologicals, Littleton, CO, USA) and subsequently incubated with peroxidase-conjugated secondary antibodies (Dako). The immunocomplex was visualized with ECL Prime chemiluminescence (GE Health, Buckinghamshire, UK) using the ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). Quantification of protein bands was performed by the ImageJ program (National Institutes of Health, Bethesda, MD, USA) and was normalized to the b-actin level.
Measurement of TGF-b1 secretion
Culture supernatant was collected after 24 h of treatment. The TGF-b1 level was quantified by ELISA using a commercial kit (R&D Systems).
Statistical analysis
All the data are expressed as mean 6 SEM. Differences between multiple groups were evaluated with one-way analysis of variance followed by Bonferroni's comparison using GraphPad Prism version 4 (GraphPad Software, La Jolla, CA, USA). Data were considered statistically significant at P < 0.05.
R E S U L T S Complement C5a deposition is increased in renal biopsies of patients with DN
To study the role of C5a in human DN, we compared the levels of complement C5a and its receptor C5aR between diabetic kidney tissue (n ¼ 10) and non-diabetic healthy controls (n ¼ 5) by immunohistochemical staining. Complement C5a was mainly detected in association with renal tubules and to a lesser extent in glomeruli from non-diabetic normal kidney ( Figure 1A) . Renal biopsies from patients with DN showed more intense staining of C5a in the tubules but no significant change in C5a level in the glomeruli ( Figure 1B) . In contrast to C5a, expression of C5aR was exclusively detected in renal tubules, but the intensity of C5aR staining was similar between normal ( Figure 1C ) and diabetic renal tissues ( Figure 1D ). There was a significant difference between C5a staining in renal biopsies from patients at different stages of DN. The tubular C5a staining was significantly higher in patients with advanced DN and diagnosed with marked tubular atrophy and interstitial fibrosis than in patients with mild or moderate DN ( Figure 1F ). In the animal model, we found a significant increase in serum C5a level in diabetic db/db mice ( Figure 1G ) and a slight upregulation of C5aR gene expression in renal cortical tissue ( Figure 1H ).
Administration of NOX-D21 improves renal function and reduces renal damage in db/db mice
At the age of 10 weeks, all db/db mice had already developed diabetes, with significantly higher body weight and fasting blood glucose levels than in non-diabetic db/m mice. These diabetic mice also developed proteinuria with significantly increased serum creatinine levels. To evaluate whether blockade of endogenous C5a would affect the progression of DN, we treated db/db mice with a novel C5a inhibitor (NOX-D21) for 12 weeks. Our data showed that treatment with NOX-D21 slightly reduced the blood glucose level in db/db mice, but this trend did not reach statistical significance, whereas NOX-D21 significantly prevented an increase in serum creatinine and BUN levels in db/db mice. However, NOX-D21 caused no change in albuminuria between the two groups of diabetic mice ( Table 2) . PAS staining showed notable morphological changes in the vehicle-treated db/db Role of complement C5a in DN mice, including diffused mesangial matrix expansion, increased tubulointerstitial lesions and tubular dilation, which were reduced after treatment with NOX-D21 (Figure 2A ). Semiquantitative analysis of glomerulosclerosis ( Figure 2B ) and tubulointerstitial damage ( Figure 2C ) confirmed the renoprotective effect of NOX-D21 in diabetic kidneys.
NOX-D21 attenuates TGF-b1 signalling and extracellular matrix accumulation in diabetic kidney
To dissect the protective mechanism of C5a inhibition in diabetic kidney, we first examined renal inflammation and showed an increased level of macrophage (F4/80 þ cells) infiltration into renal tissue of db/db mice. However, NOX-D21 had no significant effect on the degree of macrophage infiltration between vehicle-and NOX-D21-treated groups ( Figure 3A) . Although the expression of inflammation-related genes, including TNF-a and intracellular adhesion molecule-1 (ICAM-1), was upregulated in db/db mice, no expression difference was found between the vehicle-or NOX-D21-treated groups ( Figure 3B ). However, we found that Fn and type 1 collagen (COL1) expression was reduced in diabetic kidney (Figure 4 ) and the upregulated gene expression of TGF-b1, Fn and COL1 was markedly attenuated by NOX-D21 ( Figure 5A ). Similar results with reduced TGF-b1 and extracellular matrix (ECM) proteins were detected by western blot analysis ( Figure 5B ).
C5a is associated with activated Akt signalling and TGFb1 expression in HK-2 cells
Our in vivo study showed that administration of NOX-D21 suppressed the increased level of Akt phosphorylation in db/db kidney ( Figure 6A ). To elucidate the role of C5a in vitro, we stimulated HK-2 cells with C5a protein and found an increased phosphorylation of Akt at Ser473 as early as 5 min, reaching a peak at 10 min ( Figure 6B ). Inconsistent with our animal study, stimulation with C5a did not induce inflammatory responses in HK-2 cells (data not shown), but increased the expression of TGF-b1 protein. Pretreatment with PI3K inhibitor (LY294002) inhibited C5a-induced TGF-b1 secretion ( Figure 6C ). These data suggest a role of C5a in regulating TGF-b1 expression via the PI3K/Akt signalling pathway in HK-2 cells.
NOX-D21 reduces lipid metabolism and accumulation in db/db mice
As shown in Table 2 , there was a decreasing trend in blood glucose level in NOX-D21-treated db/db mice when compared with vehicle-treated db/db mice. Administration of NOX-D21 also resulted in a significant decrease in the serum triglyceride level in db/db mice ( Figure 7A ) but no difference in the serum cholesterol level between the two groups ( Figure 7B ). Western blot analysis showed a marked increase in ADRP expression in diabetic kidney, indicating heavy lipid deposition in Role of complement C5a in DN the vehicle-treated db/db mice. Treatment with NOX-D21 significantly reduced the level of ADRP in diabetic kidney ( Figure  7C ), accompanied by decreased mRNA expression of diacylglycerolacyltransferase-1 (DGAT1) and sterol-regulatory element binding protein-1 (SREBP-1), the major regulators of renal lipid metabolism. However, NOX-D21 had no effect on the expression of DGAT2 ( Figure 7D ).
D I S C U S S I O N
Complement C5a contributes to the glomerular injury in different forms of glomerulonephritis [23] and in renal transplantation, causing inflammation and late apoptosis during ischaemia-reperfusion injury and adaptive immune responses in allograft rejection [24] . In past decades, therapeutic strategies using an anti-C5 antibody have proven effective in nephritis NOX-D21 reduced tubulointerstitial fibrosis in db/db mice. Representative renal sections with immunohistochemical staining of fibronectin (Fn) and type 1 collagen (COL1) from db/m (n ¼ 5), db/db (vehicle) (n ¼ 6) and db/db (NOX-D21) (n ¼ 6) mice. Bar ¼ 100 mm. Quantitative analysis was performed using Image-Pro Plus 6.0 software. and ischaemia-reperfusion injuries [25] . However, little is known about the role of C5a activation in DN that could unmask its therapeutic potential in CKD.
In this study we found that C5a deposition was increased in tubules of renal biopsies obtained from patients with DN. C5a is a potent chemoattractant for neutrophils and macrophages that cause local inflammation in the kidney. In fact, the recruitment of macrophages in interstitium or glomeruli is a characteristic feature of DN [26] . More importantly, our data revealed that the renal C5a level increased with the severity of tubular injury and interstitial fibrosis in patients with DN, suggesting a strong and positive correlation between C5a signalling and the progression of DN. In another study, renal C5a deposition and C5aR expression were significantly correlated with renal pathology in IgA nephropathy patients [19] . Taken together, we suggest that activation of C5a/C5aR signalling may be a common mechanism for the progression of CKD. In contrast to IgA nephropathy patients, our results showed an increase of C5a but not C5aR expression in human diabetic kidney. Both C5a and C5aR were mainly detected in renal tubules, indicating a key role for C5a/C5aR signalling in tubular cells. Although data from another group demonstrated increased C5aR expression in glomerular endothelial cells of patients with advanced DN [27] , the importance of C5/C5aR signalling in glomerular lesions was not as critical as in tubular injury since there was no significant difference in the degree of mesangial matrix expansion between wild-type and C5aR knockout mice in progressive glomerulonephritis [28] .
The pathogenic role of C5a in diabetic microvascular complications was demonstrated in patients with proliferative diabetic retinopathy in which there was a correlation between vitreous C5a concentration and vascular endothelial growth factor as well as CCL-2 levels [29] , suggesting its role in inflammation and angiogenesis. Increasing evidence shows that C5a mediates the development of renal fibrosis in the experimental models of UUO [20] , ischaemia-reperfusion injury [30] and chronic pyelonephritis [31] . Although the pro-inflammatory and pro-fibrotic role of C5a has been implicated in various renal diseases and blockade with a C5aR antagonist has demonstrated its potential value in acute kidney allograft rejection [17] , the UUO model [20] and lupus nephritis [18] , we for the first time showed that inhibition of C5a signalling could further ameliorate DN.
In agreement with our hypothesis, levels of C5a and C5aR were increased in db/db mice and C5a contributes to glomerular injury, as less glomerulosclerosis was found in NOX-D21-treated db/db mice. Although the expression of C5a and C5aR in glomerular cells was not that significant as in the tubules in DN, C5a/C5aR antagonism has been shown to inhibit proliferation and cytokine production in glomerular mesangial cells in other studies [32] and C5a/C5aR activation increases protein permeability in kidney endothelial cells and regulates proteinuria in disease models [33] . However, our data did not show any , db/db (vehicle) (n ¼ 10) and db/db (NOX-D21) (n ¼ 10) mice. Quantitative analysis was performed using ImageJ. *P < 0.05; **P < 0.01; ***P < 0.001 compared with db/m; # P < 0.05 compared with db/db (vehicle) mice.
Role of complement C5a in DN effect of NOX-D21 on proteinuria. This may be due to the dominant expression of C5aR on the tubular compartment rather than in the glomerular area during DN. Indeed, we provide evidence on the importance of C5a/C5aR signalling in tubular cells to the progression of renal fibrosis. Administration of NOX-D21 reduced ECM accumulation and prevented tubulointerstitial fibrosis, it also improved renal functions in db/db mice. We also found that C5a stimulated TGF-b secretion in HK-2 cells through activation of the PI3K/Akt pathway.
Upregulation of phosphorylated Akt levels and overexpression of TGF-b1 were confirmed in the db/db kidney, which disappeared after C5a inhibition. Activation of the PI3K/Akt signalling pathway in kidney injury has been associated with renal cell proliferation, fibroblast activation and matrix production [34] . Importantly, evidence has shown that Akt activation contributes to renal fibrosis by promoting tubular epithelial-mesenchymal transition, a process that is induced by TGF-b1 and has been shown to trigger collagen production [35] . Taken together, our present data support the pro-fibrotic effect of C5a in renal fibrosis via Akt-mediated TGF-b1 production.
Blockade of C5a/C5aR signalling did not result in decreased macrophage infiltration and pro-inflammatory cytokine production in db/db mice. Another study also showed that C5 deficiency had no effect on the severity of pancreatitis, but less fibrosis was developed in a later stage of disease [36] . This can be explained by the controversial role of C5a in inflammation. Although C5a induces pro-inflammatory responses via C5aR, it has been reported that it exhibits anti-inflammatory function by binding to C5L2 [37] . There may be a compensation process by other complement components or inflammatory molecules.
Despite the protective effect of C5a inhibition on tubulointerstitial fibrosis, our data suggest that NOX-D21 ameliorates altered lipid metabolism in diabetic mice. The serum triglyceride level of diabetic mice was significantly lower in the presence of NOX-D21, indicating that it inhibits C5a/Ca5R activation in other cell types that are involved in fatty acid metabolism. Previous studies demonstrated the contribution of C5aR in lipid metabolism in adipose tissue, skeletal muscle and liver in an animal model of high-fat high-sucrose diet-induced obesity [38] and C5aR-mediated inflammation and insulin resistance in adipose tissue [39] . Therefore, blockade of C5a/C5aR signalling may modulate fatty acid metabolism in adipocyte tissue of diabetic mice, thereby lowering the serum triglyceride level and its uptake by renal epithelial cells. Since dyslipidaemia causes a direct deleterious effect through renal lipotoxicity, renal lipid accumulation leads to cellular dysfunction, particularly in renal epithelial cells, and the progression of DN [40, 41] . We demonstrated the downregulation of DGAT1 and SREBP-1 expression (key regulators in fatty acid synthesis) and a marker of cytoplasmic oil droplets (ADRP) after C5a inhibition, indicating reduced fat storage and improved renal lipid metabolism in diabetic kidney.
Currently the potential of anti-C5 antibody therapy with eculizumab in kidney transplant [42] and lupus nephritis is undergoing clinical trials [43] . Another C5aR inhibitor, CCX168, is being clinically tested for the treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis and has shown improvements in urinary albumin:creatinine ratio and estimated glomerular filtration rate. Our study suggests a pathogenic role of C5a in the development of DN by dysregulating fatty acid metabolism in diabetes and promoting a pro-fibrotic pathway in tubular epithelial cells. Inhibition of C5a signalling with NOX-D21 partially ameliorates lipid metabolic abnormality, improves renal function and attenuates the progression of renal fibrosis. These data provide support for anti-C5 therapy in DN in the future. 
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